Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Recent research has highlighted the significant role of Omega-3 fatty acids in supporting heart health, including some ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...